These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 26261098)

  • 1. Fluorogenic Assay for Inhibitors of HIV-1 Protease with Sub-picomolar Affinity.
    Windsor IW; Raines RT
    Sci Rep; 2015 Aug; 5():11286. PubMed ID: 26261098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological evaluation of novel amprenavir-based P1-substituted bi-aryl derivatives as ultra-potent HIV-1 protease inhibitors.
    Yan J; Huang N; Li S; Yang LM; Xing W; Zheng YT; Hu Y
    Bioorg Med Chem Lett; 2012 Mar; 22(5):1976-9. PubMed ID: 22306123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The higher barrier of darunavir and tipranavir resistance for HIV-1 protease.
    Wang Y; Liu Z; Brunzelle JS; Kovari IA; Dewdney TG; Reiter SJ; Kovari LC
    Biochem Biophys Res Commun; 2011 Sep; 412(4):737-42. PubMed ID: 21871444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
    Lefebvre E; Schiffer CA
    AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and virtual phenotypic resistance patterns: an independent cohort analysis of clinical isolates highly resistant to all other protease inhibitors.
    Talbot A; Grant P; Taylor J; Baril JG; Liu TF; Charest H; Brenner B; Roger M; Shafer R; Cantin R; Zolopa A
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2473-9. PubMed ID: 20368406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of protease inhibitor combinations in vitro: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates.
    Bulgheroni E; Citterio P; Croce F; Lo Cicero M; Viganò O; Soster F; Chou TC; Galli M; Rusconi S
    J Antimicrob Chemother; 2004 Mar; 53(3):464-8. PubMed ID: 14963061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization.
    Koh Y; Matsumi S; Das D; Amano M; Davis DA; Li J; Leschenko S; Baldridge A; Shioda T; Yarchoan R; Ghosh AK; Mitsuya H
    J Biol Chem; 2007 Sep; 282(39):28709-28720. PubMed ID: 17635930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substituted Bis-THF Protease Inhibitors with Improved Potency against Highly Resistant Mature HIV-1 Protease PR20.
    Agniswamy J; Louis JM; Shen CH; Yashchuk S; Ghosh AK; Weber IT
    J Med Chem; 2015 Jun; 58(12):5088-95. PubMed ID: 26010498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration.
    Salcedo Gómez PM; Amano M; Yashchuk S; Mizuno A; Das D; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6110-21. PubMed ID: 24080647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use.
    Brower ET; Bacha UM; Kawasaki Y; Freire E
    Chem Biol Drug Des; 2008 Apr; 71(4):298-305. PubMed ID: 18312292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enamino-oxindole HIV protease inhibitors.
    Eissenstat M; Guerassina T; Gulnik S; Afonina E; Silva AM; Ludtke D; Yokoe H; Yu B; Erickson J
    Bioorg Med Chem Lett; 2012 Aug; 22(15):5078-83. PubMed ID: 22749283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging HIV-1 resistance to tipranavir and darunavir in patients with virological failure to first-generation protease inhibitors in Taiwan.
    Hsieh SM; Chang SY; Hung CC; Sheng WH; Chen MY; Chang SC
    Int J STD AIDS; 2011 Nov; 22(11):617-20. PubMed ID: 22096044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genotypic and phenotypic evolution of HIV type-1 protease during in vitro sequential or concomitant combination of atazanavir and amprenavir.
    Cunyat F; Ruiz L; Marfil S; Puig T; Bofill M; Blanco J; Clotet B; Cabrera C
    Antivir Ther; 2010; 15(3):431-6. PubMed ID: 20516562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A conserved hydrogen-bonding network of P2 bis-tetrahydrofuran-containing HIV-1 protease inhibitors (PIs) with a protease active-site amino acid backbone aids in their activity against PI-resistant HIV.
    Yedidi RS; Garimella H; Aoki M; Aoki-Ogata H; Desai DV; Chang SB; Davis DA; Fyvie WS; Kaufman JD; Smith DW; Das D; Wingfield PT; Maeda K; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2014 Jul; 58(7):3679-88. PubMed ID: 24752271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir.
    Baxter JD; Schapiro JM; Boucher CA; Kohlbrenner VM; Hall DB; Scherer JR; Mayers DL
    J Virol; 2006 Nov; 80(21):10794-801. PubMed ID: 16928764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Modified P1 Moiety Enhances In Vitro Antiviral Activity against Various Multidrug-Resistant HIV-1 Variants and In Vitro Central Nervous System Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413.
    Amano M; Salcedo-Gómez PM; Zhao R; Yedidi RS; Das D; Bulut H; Delino NS; Sheri VR; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7046-7059. PubMed ID: 27620483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease.
    Ohtaka H; Velázquez-Campoy A; Xie D; Freire E
    Protein Sci; 2002 Aug; 11(8):1908-16. PubMed ID: 12142445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of wild-type and mutant human immunodeficiency virus type 1 proteases by GW0385 and other arylsulfonamides.
    Hanlon MH; Porter DJ; Furfine ES; Spaltenstein A; Carter HL; Danger D; Shu AY; Kaldor IW; Miller JF; Samano VA
    Biochemistry; 2004 Nov; 43(45):14500-7. PubMed ID: 15533054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Solution kinetics measurements suggest HIV-1 protease has two binding sites for darunavir and amprenavir.
    Kovalevsky AY; Ghosh AK; Weber IT
    J Med Chem; 2008 Oct; 51(20):6599-603. PubMed ID: 18808097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants.
    Altman MD; Ali A; Reddy GS; Nalam MN; Anjum SG; Cao H; Chellappan S; Kairys V; Fernandes MX; Gilson MK; Schiffer CA; Rana TM; Tidor B
    J Am Chem Soc; 2008 May; 130(19):6099-113. PubMed ID: 18412349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.